Statistics in Biopharmaceutical Research Best Papers Award 2023

IF 1.5 4区医学 Q3 MATHEMATICAL & COMPUTATIONAL BIOLOGY

Statistics in Biopharmaceutical Research Pub Date : 2023-04-03 DOI:10.1080/19466315.2023.2200112

T. Hamasaki, Freda Cooner

引用次数: 0

Abstract

We are pleased to announce the recipients of the 2023 Best Paper Award for the articles published in Statistics in Biopharmaceutical Research (SBR). The following five articles were selected from those published in the 2021 and 2022 issues. These articles exhibit excellent examples of current statistical advancements in biopharmaceutical research. In selecting the winners, the editors reflected SBRs goal of publishing articles that focus on the development of novel statistical methods, advanced applications of existing methods

查看原文本刊更多论文

生物制药研究统计学最佳论文奖2023

我们很高兴地宣布2023年最佳论文奖的获得者，他们发表在《生物制药研究统计》(SBR)上的文章。以下五篇文章是从2021年和2022年出版的文章中挑选出来的。这些文章展示了生物制药研究中当前统计进展的极好例子。在选择获奖者时，编辑们反映了sbr的目标，即发表专注于发展新颖统计方法和现有方法的先进应用的文章

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Statistics in Biopharmaceutical Research MATHEMATICAL & COMPUTATIONAL BIOLOGY-STATISTICS & PROBABILITY

CiteScore

3.90

自引率

16.70%

发文量

期刊介绍： Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems. Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application). The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review. Authors can choose to publish gold open access in this journal.